Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Status: Enrolling
Updated:  2/4/2016
Advanced Aesthetics
mi
from
Bensalem, PA
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Status: Enrolling
Updated: 2/4/2016
Advanced Aesthetics
mi
from
Bensalem, PA
Click here to add this to my saved trials
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Status: Enrolling
Updated:  2/4/2016
Jefferson Dermatology Associates
mi
from
Philadelphia, PA
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas
Status: Enrolling
Updated: 2/4/2016
Jefferson Dermatology Associates
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
La Jolla, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
San Francisco, CA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Aurora, CO
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lakeland, FL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lakeland, FL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Orlando, FL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Park Ridge, IL
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Indianapolis, IN
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lutherville, MD
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lutherville, MD
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Boston, MA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Buffalo, NY
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
New York, NY
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Charlotte, NC
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Houston, TX
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
Clinical Research Facility
mi
from
Madison, WI
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated:  2/7/2016
mi
from
Brisbane,
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma
Status: Enrolling
Updated: 2/7/2016
mi
from
Brisbane,
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
University of Colorado Dept of Oncology
mi
from
Aurora, CO
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
University of Colorado Dept of Oncology
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
Oregon Health & Science University Dept. of OHSU (3)
mi
from
Portland, OR
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
Oregon Health & Science University Dept. of OHSU (3)
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
Vanderbilt University Medical Center SC - Dept of Oncology .
mi
from
Nashville, TN
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
Vanderbilt University Medical Center SC - Dept of Oncology .
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
Karmanos Cancer Institute Dept of Oncology
mi
from
Detroit, MI
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
Karmanos Cancer Institute Dept of Oncology
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
Memorial Sloan Kettering Cancer Center Dept Oncology
mi
from
NY, NY
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
Memorial Sloan Kettering Cancer Center Dept Oncology
mi
from
NY, NY
Click here to add this to my saved trials
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated:  2/11/2016
Novartis Investigative Site
mi
from
Westmead,
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.
Status: Enrolling
Updated: 2/11/2016
Novartis Investigative Site
mi
from
Westmead,
Click here to add this to my saved trials
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  2/11/2016
Dana Farber Cancer Institute Dept of Onc
mi
from
Boston, MA
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 2/11/2016
Dana Farber Cancer Institute Dept of Onc
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  2/11/2016
Memorial Sloan Kettering Cancer Center Dept Onc
mi
from
NY, NY
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 2/11/2016
Memorial Sloan Kettering Cancer Center Dept Onc
mi
from
NY, NY
Click here to add this to my saved trials
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated:  2/11/2016
Novartis Investigative Site
mi
from
Paris,
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Status: Enrolling
Updated: 2/11/2016
Novartis Investigative Site
mi
from
Paris,
Click here to add this to my saved trials
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Status: Enrolling
Updated:  2/11/2016
Sarah Cannon Research Institute Onc Dept
mi
from
Nashville, TN
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Status: Enrolling
Updated: 2/11/2016
Sarah Cannon Research Institute Onc Dept
mi
from
Nashville, TN
Click here to add this to my saved trials
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Status: Enrolling
Updated:  2/11/2016
Novartis Investigative Site
mi
from
East Melbourne,
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma
Status: Enrolling
Updated: 2/11/2016
Novartis Investigative Site
mi
from
East Melbourne,
Click here to add this to my saved trials
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated:  2/11/2016
Clinical Research Facility
mi
from
Aurora, CO
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated: 2/11/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated:  2/11/2016
Clinical Research Facility
mi
from
Boston, MA
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated: 2/11/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated:  2/11/2016
mi
from
Belo Horizonte,
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma
Status: Enrolling
Updated: 2/11/2016
mi
from
Belo Horizonte,
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Aurora, CO
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Louisville, KY
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Boston, MA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Henderson, NV
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Lebanon, NH
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
New York, NY
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Cleveland, OH
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Portland, OR
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  2/16/2016
Clinical Research Facility
mi
from
Philadelphia, PA
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 2/16/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials